ATE79030T1 - Arzneimittel mit guter stabilitaet. - Google Patents

Arzneimittel mit guter stabilitaet.

Info

Publication number
ATE79030T1
ATE79030T1 AT89105625T AT89105625T ATE79030T1 AT E79030 T1 ATE79030 T1 AT E79030T1 AT 89105625 T AT89105625 T AT 89105625T AT 89105625 T AT89105625 T AT 89105625T AT E79030 T1 ATE79030 T1 AT E79030T1
Authority
AT
Austria
Prior art keywords
drug
good stability
microcrystalline cellulose
binder
pravastatin
Prior art date
Application number
AT89105625T
Other languages
English (en)
Inventor
Yatindra Mohan Joshi
Pierina Chiesa
Nemichand Bherulal Jain
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22643088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE79030(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Application granted granted Critical
Publication of ATE79030T1 publication Critical patent/ATE79030T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vending Machines For Individual Products (AREA)
  • Formation And Processing Of Food Products (AREA)
AT89105625T 1988-03-31 1989-03-30 Arzneimittel mit guter stabilitaet. ATE79030T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/176,127 US5030447A (en) 1988-03-31 1988-03-31 Pharmaceutical compositions having good stability
EP89105625A EP0336298B1 (de) 1988-03-31 1989-03-30 Arzneimittel mit guter Stabilität

Publications (1)

Publication Number Publication Date
ATE79030T1 true ATE79030T1 (de) 1992-08-15

Family

ID=22643088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89105625T ATE79030T1 (de) 1988-03-31 1989-03-30 Arzneimittel mit guter stabilitaet.

Country Status (14)

Country Link
US (1) US5030447A (de)
EP (1) EP0336298B1 (de)
CN (1) CN1026861C (de)
AT (1) ATE79030T1 (de)
AU (1) AU624117B2 (de)
CA (1) CA1323836C (de)
CY (1) CY1675A (de)
DE (1) DE68902344T2 (de)
DK (1) DK173862B1 (de)
HK (1) HK40093A (de)
IE (1) IE62956B1 (de)
NZ (1) NZ228076A (de)
SG (1) SG107292G (de)
ZA (1) ZA891424B (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
GR1002098B (en) * 1989-06-08 1995-12-28 Squibb & Sons Inc Pharmaceutical composition having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU221849B1 (hu) * 1991-12-12 2003-02-28 Novartis Ag. HMG-CoA reduktáz inhibitor fluvasztatint tartalmazó stabilizált gyógyszerkészítmények
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
EP0812195B1 (de) 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Arzneizubereitungen für piperidinalkanolderivate
DE122011000014I1 (de) * 1995-12-22 2011-11-03 Kowa Co Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium.
EP0839526A3 (de) 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Festes pharmazeutisches Präparat mit schneller Auflösungs- oder Disintegrationeigenschaften
DE19724123A1 (de) 1997-06-09 1998-12-10 Voith Sulzer Papiermasch Gmbh Vorrichtung und Verfahren zum Überführen eines Einfädelstreifens oder einer Materialbahn
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
NZ504994A (en) * 1997-12-22 2002-10-25 Schering Corp Orally administrable rapidly dissolving solid ribavirin dosage forms
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
KR100281521B1 (ko) * 1998-03-31 2001-02-15 김종인 프라바스타틴나트륨이 함유된 약제 조성물
US6328994B1 (en) 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US6232351B1 (en) * 1998-05-22 2001-05-15 Amway Corporation Co-processed botanical plant composition
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
TWI257311B (en) 1998-07-28 2006-07-01 Takeda Chemical Industries Ltd Rapidly disintegrable solid preparation
US5985907A (en) * 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6838091B2 (en) 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
US6391583B1 (en) 1998-12-18 2002-05-21 Wisconsin Alumni Research Foundation Method of producing antihypercholesterolemic agents
US7014864B1 (en) 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
CA2367995A1 (en) * 1999-03-31 2000-10-05 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU5328701A (en) * 2000-04-10 2001-10-23 Teva Pharma Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
CZ20024015A3 (cs) 2000-06-09 2003-04-16 Lek Pharmaceutical D.D. Stabilní farmaceutický produkt a jeho formulace
ATE260101T1 (de) 2000-06-09 2004-03-15 Lek Tovarna Farmacevtskih Stabilisierte pharmazeutisch wirksame zubereitung und diese enthaltende arzneizusammensetzung
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US20020183383A1 (en) * 2001-02-27 2002-12-05 Rene Belder Pharmaceutical compositions
PL369268A1 (en) * 2001-03-27 2005-04-18 Ranbaxy Laboratories Limited A stable pharmaceutical composition of pravastatin
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
WO2003000177A2 (en) * 2001-06-21 2003-01-03 Andrx Pharmaceuticals, Inc. Stable controlled release pharmaceutical compositions containing pravastatin
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
WO2003057195A1 (en) * 2002-01-11 2003-07-17 Athpharma Limited Pravastatin pharmaceutical formulations and methods of their use
EP1905431A1 (de) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pharmazeutische Pravastatin-Formulierungen und Verfahren zu ihrer Verwendung
US20050089572A1 (en) * 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
WO2003088900A2 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Solid forms of salts with tyrosine kinase activity
EP1551356A2 (de) * 2002-09-03 2005-07-13 Biovail Laboratories Incorporated Pravastatin zubereitungen und deren verwendung
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
BR0309691A (pt) 2002-12-20 2005-08-02 Hoffmann La Roche Formulação de ibandronato em alta dose
DE60331873D1 (de) 2002-12-20 2010-05-06 Pfizer Prod Inc Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
US20040225018A1 (en) * 2003-03-17 2004-11-11 Japan Tobacco Inc. Pharmaceutical compositions of CETP inhibitors
EP1603554A1 (de) * 2003-03-17 2005-12-14 Japan Tobacco Inc. Methode zur verbesserung der oralen bioverfuegbarkeit von s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanthioat
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
EP1673336B1 (de) 2003-08-21 2014-06-04 Merck Canada Inc. Cathepsincysteinproteasehemmer
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
WO2006008757A2 (en) * 2004-05-05 2006-01-26 Cadila Healthcare Limited Stabilized pharmaceutical compositions of pravastatin
BRPI0514189A (pt) * 2004-08-06 2008-06-03 Transform Pharmaceuticals Inc composições farmacêuticas de estatina e métodos de tratamento relacionados
US20090149533A1 (en) * 2004-08-06 2009-06-11 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
CN100453116C (zh) * 2004-10-19 2009-01-21 上海中西制药有限公司 复方氨茶碱片剂及其制备方法
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
WO2006062876A2 (en) 2004-12-09 2006-06-15 Merck & Co., Inc. Estrogen receptor modulators
EP1855674B1 (de) 2005-03-02 2014-07-16 Merck Sharp & Dohme Corp. Zusammensetzung zur hemmung von cathepsin k
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
TW200813039A (en) 2006-04-19 2008-03-16 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
EP1911441A3 (de) * 2006-10-11 2008-08-06 Lupin Limited Farbstabile pharmazeutische Dosierungsformen mit kontrollierter Freigabe von HMG-COA-Reduktase-Hemmern, die frei von Alkalisierungs- oder Pufferagenzien sind
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
AP2009005026A0 (en) * 2007-04-09 2009-12-31 Scidose Llc Combinations of statins and anti-obesity agent
KR20100017866A (ko) 2007-05-21 2010-02-16 노파르티스 아게 Ｃｓｆ－１ｒ 억제제, 조성물 및 사용 방법
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2489656A1 (de) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selektive Androgenrezeptormodulatoren (SARMS) und ihre Verwendung
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
CN101732267B (zh) * 2008-11-14 2012-05-30 丽珠医药集团股份有限公司 普伐他汀钠片剂、其用途及其制备方法
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
WO2012002464A1 (ja) * 2010-06-30 2012-01-05 持田製薬株式会社 ω３脂肪酸の配合製剤
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2675440B1 (de) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin-cysteinproteasehemmer
WO2012141160A1 (ja) 2011-04-12 2012-10-18 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
IN2013MN02170A (de) 2011-04-21 2015-06-12 Piramal Entpr Ltd
WO2012153181A1 (en) * 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
TWI636783B (zh) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
IN2013MU02470A (de) * 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN105593230B (zh) 2013-10-08 2018-07-06 默沙东公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10413543B2 (en) * 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112022012032A2 (pt) 2019-12-17 2022-09-06 Merck Sharp & Dohme Llc Inibidores de prmt5
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865935A (en) * 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US3891755A (en) * 1973-07-11 1975-06-24 Abbott Lab Dosage formulation for erythromycin cetyl sulfate
US4342767A (en) * 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4681759A (en) * 1985-05-08 1987-07-21 Ortho Pharmaceutical Corporation Rioprostil-PVP complex
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments

Also Published As

Publication number Publication date
AU624117B2 (en) 1992-06-04
JPH026406A (ja) 1990-01-10
EP0336298A1 (de) 1989-10-11
CN1036508A (zh) 1989-10-25
DK173862B1 (da) 2002-01-07
NZ228076A (en) 1991-04-26
ZA891424B (en) 1989-10-25
AU3027689A (en) 1989-10-05
DK155689D0 (da) 1989-03-30
CY1675A (en) 1993-10-10
DK155689A (da) 1989-10-01
DE68902344D1 (de) 1992-09-10
CA1323836C (en) 1993-11-02
HK40093A (en) 1993-04-30
SG107292G (en) 1992-12-24
DE68902344T2 (de) 1993-01-07
IE890929L (en) 1989-09-30
EP0336298B1 (de) 1992-08-05
US5030447A (en) 1991-07-09
JP2935220B2 (ja) 1999-08-16
IE62956B1 (en) 1995-03-08
CN1026861C (zh) 1994-12-07

Similar Documents

Publication Publication Date Title
ATE79030T1 (de) Arzneimittel mit guter stabilitaet.
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
DK0698389T3 (da) Matrix med reguleret frigivelse til farmaceutiske præparater
BR9810984A (pt) Composto de triazol, uso do mesmo, e, composição farmacêutica
AR064896A2 (es) Composicion farmaceutica no higroscopica
DE69028109D1 (de) Medizinische beatmungsgeräte
ATE66143T1 (de) Feste zubereitung mit langsamer freisetzung.
DE3772924D1 (de) Gegen oxydierung und verfaerbung stabilisierte arzneimittelzubereitungen.
SE8804629D0 (sv) New therapeutically active compounds
DK0724885T3 (da) Pernasal sammensætning og pernasalt præparat indeholdende dette
DE58906867D1 (de) Wässrige Dispersion von 2-(2'-Hydroxyphenyl-)benzotriazolen.
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
SE8804628D0 (sv) New compounds
AU2437388A (en) 2, 3-Dihydro-2, 2-dimethyl-3-hydroxy-6-(trifluoroalkoxy)-4- amino derivatives
DE3781488D1 (de) Pharmazeutische zusammensetzung, enthaltend 2',3'-dideoxycytidin-2'-en(2',3'-dideoxy-2',3'-didehydrocytidin) zur behandlung von mit retrovirus infizierten patienten.
DE3871791D1 (de) Verwendung von homo- und copolymeren des vinylalkohols zum tablettieren von wirkstoffen.
CO5031291A1 (es) Composicion farmaceutica
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
DE3867042D1 (de) Pharmazeutische praeparate.
AU5326190A (en) 2-substituted N,N'-ditrimethoxybenzoyl piperazines, and therapeutic compositions containing them
FR2714603B1 (fr) Composition dermatologique et son utilisation pour la préparation d'un médicament.
GR890100379A (el) Φαρμακευτικές συνθέσεις έχοντας καλή σταθερότητα.
DK623984D0 (da) Farmaceutisk doseringsenhed
KR880002520A (ko) 망막증의 치료방법
KR900012622A (ko) 피부질환치료 조성물

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time